Compass Therapeutics (CMPX) Consolidated Net Income (2023 - 2025)
Historic Consolidated Net Income for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$15.8 million.
- Compass Therapeutics' Consolidated Net Income fell 2923.44% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 4154.73%. This contributed to the annual value of -$56.6 million for FY2024, which is 3325.41% down from last year.
- Per Compass Therapeutics' latest filing, its Consolidated Net Income stood at -$15.8 million for Q3 2025, which was down 2923.44% from -$21.1 million recorded in Q2 2025.
- In the past 5 years, Compass Therapeutics' Consolidated Net Income ranged from a high of -$7.8 million in Q1 2023 and a low of -$21.1 million during Q2 2025
- Over the past 3 years, Compass Therapeutics' median Consolidated Net Income value was -$13.1 million (recorded in 2024), while the average stood at -$13.5 million.
- As far as peak fluctuations go, Compass Therapeutics' Consolidated Net Income tumbled by 1594.25% in 2024, and later crashed by 6110.43% in 2025.
- Quarter analysis of 3 years shows Compass Therapeutics' Consolidated Net Income stood at -$13.4 million in 2023, then decreased by 23.55% to -$16.6 million in 2024, then grew by 4.57% to -$15.8 million in 2025.
- Its last three reported values are -$15.8 million in Q3 2025, -$21.1 million for Q2 2025, and -$16.6 million during Q1 2025.